Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Opoku Acheampong, Alexander B ^a   Unis, Dave ^a   Henningson, Jamie N ^a   Beck, Amanda P ^b   Lindshield, Brian L ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FOOD INTAKE; HISTOPATHOLOGY; LYMPH NODE METASTASIS; MALE; NONHUMAN; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; UROGENITAL SYSTEM; WEIGHT GAIN;

5-ALPHA REDUCTASE INHIBITORS; ANIMALS; AZASTEROIDS; BODY WEIGHT; CHOLESTENONE 5 ALPHA-REDUCTASE; DISEASE PROGRESSION; FINASTERIDE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25;

EID: 84885784679     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077738     Document Type: Article

References (39)

1. American Cancer Society (2013). ancer Facts Figures: pp. 2013.
2. Tien AH, Sadar MD, (2013) Androgen-responsive gene expression in prostate cancer progression. In: Androgen-Responsive Genes in Prostate Cancer. Springer Verlag. pp. 135-153.
3. Grossmann ME, Huang H, Tindall DJ, (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93(22):: 1687-1697. doi:10.1093/jnci/93.22.1687. PubMed: 11717329.
4. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, et al. (2004) Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64(3):: 537-543. doi:10.1016/j.urology.2004.04.084. PubMed: 15351586.
5. Russell DW, Wilson JD, (1994) Steroid 5alpha reductase: Two genes/two enzymes. Annu Rev Biochem 63: 25-61.
6. Luo J, Dunn TA, Ewing CM, Walsh PC, Isaacs WB, (2003) Decreased gene expression of steroid 5alpha reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate carcinoma. Prostate 57(2):: 134-139. doi:10.1002/pros.10284. PubMed: 12949937.
7. Titus MA, Gregory CW, Ford OH III, Schell MJ, Maygarden SJ, et al. (2005) Steroid 5alpha reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11(12):: 4365-4371. doi:10.1158/1078-0432.CCR-04-0738. PubMed: 15958619.
8. Söderström TG, Bjelfman C, Brekkan E, Ask B, Egevad L, et al. (2001) Messenger ribonucleic acid levels of steroid 5alpha reductase 2 in human prostate predict the enzyme activity. J Clin Endocrinol Metab 86(2):: 855-858. doi:10.1210/jc.86.2.855. PubMed: 11158057.
9. Bjelfman C, Söderström TG, Brekkan E, Norlén BJ, Egevad L, et al. (1997) Differential gene expression of steroid 5alpha reductase 2 in core needle biopsies from malignant and benign prostatic tissue. J Clin Endocrinol Metab 82(7):: 2210-2214. doi:10.1210/jc.82.7.2210. PubMed: 9215296.
10. Iehlé C, Radvanyi F, Diez de Medina Gil S, Ouafik LH, Gerard H,et al (1999) Differences in steroid 5alpha reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68(5-6):: 189-195. doi:10.1016/S0960-0760(99)00030-8. PubMed: 10416833.
11. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, et al. (2005) In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12(1):: 101-107. doi:10.1677/erc.1.00914. PubMed: 15788642.
12. Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, et al. (2003) The loss of 5alpha reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin Cancer Res 9(5):: 1815-1819. PubMed: 12738739.
13. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, et al. (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349(3):: 215-224. doi:10.1056/NEJMoa030660. PubMed: 12824459.
14. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, et al. (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362: 1192-1202. doi:10.1056/NEJMoa0908127. PubMed: 20357281.
15. FDA Drug Safety Communication: 5alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. Retrieved onpublished at whilst December year 1111 from http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm. Accessed 2013 September 23.
16. Pinsky PF, Black A, Grubb R, Crawford ED, Andriole G, et al. (2013) Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer 119(3):: 593-601. doi:10.1002/cncr.27774. PubMed: 22893105.
17. Fleshner NE, (2012) Dutasteride and active surveillance of low-risk prostate cancer. Lancet 379(9826):: 1590. doi:10.1016/S0140-6736(12)60679-5. PubMed: 22541581.
18. Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT, (2006) Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12(13):: 4072-4079. doi:10.1158/1078-0432.CCR-06-0184. PubMed: 16818707.
19. Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, et al. (2007) Combinations of tomato and broccoli enhance antitumor activity in dunning R3327-H prostate adenocarcinomas. Cancer Res 67(2):: 836-843. doi:10.1158/0008-5472.CAN-06-3462. PubMed: 17213256.
20. Cho YM, Takahashi S, Asamoto M, Suzuki S, Tang M, et al. (2007) Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer Prostatic Dis 10(4):: 378-383. doi:10.1038/sj.pcan.4500971. PubMed: 17457304.
21. Schmidt LJ, Regan KM, Anderson SK, Sun Z, Ballman KV, et al. (2009) Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate 69(16):: 1730-1743. doi:10.1002/pros.21022. PubMed: 19676081.
22. Opoku-Acheampong AB, Nelsen MK, Unis D, Lindshield BL, (2012) The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. PLOS ONE 7(1):: e29068. doi:10.1371/journal.pone.0029068. PubMed: 22242155.
23. Costello LC, Franklin RB, Zou J, Feng P, Bok R, et al. (2011) Human prostate cancer ZIP1/zinc/citrate genetic/metabolic relationship in the TRAMP prostate cancer animal model. Cancer Biol Ther 12(12):: 1078-1084. doi:10.4161/cbt.12.12.18367. PubMed: 22156800.
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U_S_A 92(8):: 3439-3443. doi:10.1073/pnas.92.8.3439. PubMed: 7724580.
25. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, et al. (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55(3):: 219-237. doi:10.1002/pros.10215. PubMed: 12692788.
26. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM, (1999) Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2(2):: 70-75. doi:10.1038/sj.pcan.4500296. PubMed: 12496841.
27. Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, et al. (2012) A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicol Pathol 40(1):: 5-17. doi:10.1177/0192623311425062. PubMed: 22021166.
28. Zuniga KE, Clinton SK, Erdman JW Jr., (2013) The interactions of dietary tomato powder and soy germ on prostate carcinogenesis in the TRAMP model. Cancer. Prev Res (Phila) 6(6):: 548-557. doi:10.1158/1940-6207.CAPR-12-0443.
29. Shao TC, Li H, Ittmann M, Cunningham GR, (2007) Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol 178(4 Pt 1):: 1521-1527. PubMed: 17707058.
30. Prahalada S, Rhodes L, Grossman SJ, Heggan D, Keenan KP, et al. (1998) Morphological and hormonal changes in the ventral and dorsolateral prostatic lobes of rats treated with finasteride, a 5-alpha reductase inhibitor. Prostate 35(3):: 157-164. doi:10.1002/(SICI)1097-0045(19980515)35:3. PubMed: 9582084.
31. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U_S_A 92(8):: 3439-3443. doi:10.1073/pnas.92.8.3439. PubMed: 7724580.
32. Ku JH, Shin JK, Cho MC, Myung JK, Moon KC, et al. (2009) Effect of dutasteride on the expression of hyposia-inducible factor 1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Scand J Urol Nephrol 43(6):: 445-453. doi:10.3109/00365590903337896. PubMed: 19968580.
33. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, et al. (1997) Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 57(21):: 4687-4691. PubMed: 9354422.
34. Elliott CS, Shinghal R, Presti JC Jr., (2009) The influence of prostate volume on prostate-specific antigen performance: Implications for the prostate cancer prevention trial outcomes. Clin Cancer Res 15(14):: 4694-4699. doi:10.1158/1078-0432.CCR-08-2277. PubMed: 19584168.
35. Pinsky P, Parnes H, Ford L, (2008) Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer. Prev Res 1(3):: 182-186. doi:10.1158/1940-6207.CAPR-07-0007.
36. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, et al. (2008) Finasteride does not increase the risk of high-grade prostate cancer: A bias-adjusted modeling approach. Cancer. Prev Res (Phila) 1(3):: 174-181. doi:10.1158/1940-6207.CAPR-08-0092.
37. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, et al. (2007) Finasteride and high-grade prostate cancer in the prostate cancer prevention trial. J Natl Cancer Inst 99(18):: 1375-1383. doi:10.1093/jnci/djm117. PubMed: 17848673.
38. Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, et al. (2009) PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology 73(5):: 935-939. doi:10.1016/j.urology.2008.09.079. PubMed: 19328538.
39. US Environmental Protection Agency Recommended use of body weight 3/4 as the default method in derivation of the oral reference dose. Retrieved onpublished at whilst December year 1111 from http://www.epa.gov/raf/publications/interspecies-extrapolation.htm. Accessed 2013 September 23.